Bioventus Inc.

Unless the context requires otherwise, in this Annual Report on Form 10-K ( Annual Report ) the terms we, us, our, the Company, Bioventus, Bioventus Inc. and similar references refer to the combined operations of Bioventus Inc. and its consolidated subsidiaries and affiliates, including Bioventus LLC ( BV LLC ). Company Overview We are a global medical device company focused on helping patients recover and live life to the fullest by relieving pain and addressing musculoskeletal challenges through a diverse portfolio of high-quality, innovative, and clinically-proven solutions. We manage our business through two reporting segments, U.S. and International, which accounted for 88% and 12%, respectively, of our total net sales during the fiscal year ended December 31, 2025. Our portfolio of products is comprised of five patient-focused areas, grouped into three businesses based on clinical use: (i) Pain Treatments & PRP ( Pain Treatments ), (ii) Surgical Solutions and (iii) Restorative Therapies. Pain Treatments , consisting of: Knee Osteoarthritis ( KOA ) : Our product portfolio includes a range of intra-articular, hyaluronic acid ( HA ) injections that help relieve patient discomfort and improve quality of life. In the U.S., we also distribute the XCELL Platelet-Rich Plasma ( PRP ) system, a technology that is synergistic with our existing physician call points, as many surgeons who use HA also use PRP.